Risk factors and medical resource utilization in US adults hospitalized with influenza or respiratory syncytial virus in the Hospitalized Acute Respiratory Tract Infection study-Reference-Cited by-同舟云学术

Risk factors and medical resource utilization in US adults hospitalized with influenza or respiratory syncytial virus in the Hospitalized Acute Respiratory Tract Infection study

Published:2022-04-26 Issue:5 Volume:16 Page:906-915
ISSN:1750-2640
Container-title:Influenza and Other Respiratory Viruses
language:en
Short-container-title:Influenza Resp Viruses

Author:

Hartnett Jessica¹^ORCID,Donga Prina¹,Ispas Gabriela²,Vandendijck Yannick²,Anderson David¹,House Stacey³,Suner Selim⁴

Affiliation:

1. Janssen Scientific Affairs, LLC Titusville New Jersey USA

2. Janssen Research & Development Beerse Belgium

3. Department of Emergency Medicine Washington University School of Medicine St. Louis Missouri USA

4. Department of Emergency Medicine Alpert Medical School of Brown University Providence Rhode Island USA

Funder

Janssen Pharmaceuticals

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.12994

Reference44 articles.

1. Incidence, risk factors, and viral etiology of community-acquired acute lower respiratory tract infection among older adults in rural north India

2. World Health Organization.Global influenza strategy.2019.https://www.who.int/publications/i/item/9789241515320. Accessed January 3 2022.

3. National Institutes of Health National Institute of Allergy and Infectious Diseases.Respiratory syncytial virus (RSV). 2008.https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv. Accessed October 5 2021.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study;The Lancet Infectious Diseases;2024-09

2. Respiratory syncytial virus infections in adults: a narrative review;The Lancet Respiratory Medicine;2024-09

3. Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50–59 Years Compared to ≥60 Years of Age;Clinical Infectious Diseases;2024-08-05

4. Burden of respiratory syncytial virus, human metapneumovirus and influenza virus infections in Japanese adults in the Hospitalized Acute Respiratory Tract Infection study;Respiratory Investigation;2024-07

5. How Does the Burden of Respiratory Syncytial Virus Compare to Influenza in Spanish Adults?;Influenza and Other Respiratory Viruses;2024-06